Fourteen Months Off the Clock The U.S. Food and Drug Administration has launched the PreCheck pilot program, a move aimed at accelerating the approval of domestic pharmaceutical manufacturing facilities. By …
Tag:
Eli Lilly and Co
-
-
AI Market Volatility: Why Investors Are Shifting Focus from Hyperscalers to Hardware Suppliers The artificial intelligence sector experienced significant volatility this past week as investors recalibrated their expectations for the …
-
Pharmaceutical manufacturers are rapidly shifting their obesity drug pipelines toward oral medications and infrequent dosing schedules to capture a larger share of the global weight-loss market. While Eli Lilly and …
-
Stock Market Sell-Off: Chip Stocks Dropped as Jobs Report Dashes Fed Rate Cut Hopes The stock market experienced a dramatic downturn on Friday, with the S&P 500 and Nasdaq plunging …
-
The 52nd American Music Awards: Highlights, Performances and Red Carpet Trends The music industry converged for a night of celebration at the 52nd American Music Awards. As fans tuned in …
-
Market Outlook: Salesforce Earnings and the Inflation Debate As the trading week begins following the Memorial Day holiday, Wall Street is sharpening its focus on a series of critical data …
-
Eli Lilly Accuses Pentecostal Church Leaders in $200M+ Trulicity Rebate Fraud Scheme By Dr. Natalie Singh | Health Editor | May 20, 2026 Eli Lilly and Company has filed a …
-
TrumpRx Expands: Platform Adds Generic Drugs and New Pharmacy Tools The Trump administration is scaling its direct-to-consumer drug pricing platform, TrumpRx.gov, with a significant expansion of its offerings. On Monday, …
-
GLP-1 Drugs Reshape Restaurant and Food Industries The rising adoption of GLP-1 receptor agonist medications, initially designed for managing type 2 diabetes, is significantly impacting the restaurant and food industries, …
-
Lilly’s Retatrutide Shows Promise in Type 2 Diabetes Trial, Delivering Significant Weight Loss Eli Lilly and Company announced positive topline results from the TRANSCEND-T2D-1 Phase 3 clinical trial evaluating retatrutide, …
Newer Posts